About iOx Therapeutics
Founded in February 2015 by Professor Cerundolo, iOx Therapeutics is a spin-out from the University of Oxford started to commercialise discoveries made as part of a long-running collaboration between Oxford and the Ludwig Institute for Cancer Research. iOx intends to develop and commercialise multiple synthetic lipid compounds discovered by a research team led by Professor Cerundolo.
Preliminary research indicates that these compounds activate invariant natural killer T-cells (iNKT cells), which, a large body of evidence suggests, play an important role in anti-tumour immune responses. iNKT cells are a distinct class of T lymphocyte displaying a limited diversity of T-cell receptors. They recognise lipid antigens on the surface of tumour cells and produce large amounts of cytokines within hours of stimulation without the need for clonal expansion. Furthermore, iNKT cells activate multiple immune system components, including dendritic cells, T-cells and B-cells and stimulate an antigen-specific expansion of these cells.
SalvaRx has worked with Professor Cerundolo since 2014 in order to develop a comprehensive drug development strategy for iOx, and it has put in place an board of directors with expertise in pharmaceutical development, licensing, M&A and product development. The scientific advisory board has extensive experience in the development of multiple immunotherapy products which form the current standard of care, as well as the mechanism of new immunotherapy, formulation of combinations and clinical experience in the first generation of NKT therapeutics.